Sequoia Financial Advisors LLC boosted its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 20.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,694 shares of the company’s stock after buying an additional 3,565 shares during the period. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,126,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Boston Partners grew its position in Sanofi by 3.0% in the fourth quarter. Boston Partners now owns 18,246,904 shares of the company’s stock worth $883,966,000 after acquiring an additional 523,705 shares during the period. Morgan Stanley grew its position in Sanofi by 19.3% in the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock worth $374,513,000 after acquiring an additional 1,251,199 shares during the period. Invesco Ltd. grew its position in Sanofi by 2.3% in the first quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock worth $260,697,000 after acquiring an additional 112,404 shares during the period. Arrowstreet Capital Limited Partnership grew its position in Sanofi by 276.1% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after acquiring an additional 2,468,271 shares during the period. Finally, Lazard Asset Management LLC grew its position in Sanofi by 0.8% in the first quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company’s stock worth $170,536,000 after acquiring an additional 25,457 shares during the period. 10.67% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi Stock Up 1.0 %
Shares of NASDAQ SNY opened at $51.83 on Tuesday. The stock has a market cap of $130.72 billion, a P/E ratio of 18.58, a PEG ratio of 1.57 and a beta of 0.58. The company has a current ratio of 1.42, a quick ratio of 1.05 and a debt-to-equity ratio of 0.20. Sanofi has a 12-month low of $36.91 and a 12-month high of $57.82. The business’s fifty day simple moving average is $52.86 and its 200-day simple moving average is $52.28.
Sanofi Cuts Dividend
The company also recently declared an annual dividend, which was paid on Friday, June 23rd. Investors of record on Wednesday, May 31st were issued a $1.377 dividend. This represents a dividend yield of 2.94%. The ex-dividend date was Tuesday, May 30th. Sanofi’s dividend payout ratio is currently 49.46%.
Wall Street Analyst Weigh In
A number of research firms have commented on SNY. Barclays upgraded Sanofi from an “equal weight” rating to an “overweight” rating in a research note on Monday, March 27th. Deutsche Bank Aktiengesellschaft cut Sanofi from a “hold” rating to a “sell” rating in a research note on Friday, April 28th. Argus upped their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, March 27th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average price target of $91.00.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
- Five stocks we like better than Sanofi
- 3 Stocks that Analysts Continue to Upgrade into Earnings Season
- Meta Threads Its Way To New HeightsÂ
- Helen of Troy and NanoString Technologies Trade Set-ups
- Profit Taking Hits Home for Specialty Retailers
- The 3 Hot Sectors To Watch During The Summer Reporting Season
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
